Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-07
2008-09-02
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S469000
Reexamination Certificate
active
07420069
ABSTRACT:
Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
REFERENCES:
patent: 3467675 (1969-09-01), Petersen et al.
patent: 4136193 (1979-01-01), Bogeso et al.
patent: 4650884 (1987-03-01), Bogeso
patent: 4721723 (1988-01-01), Barnes et al.
patent: 4943590 (1990-07-01), Boegesoe et al.
patent: 5296507 (1994-03-01), Tanaka et al.
patent: 5683720 (1997-11-01), Myers et al.
patent: 5840334 (1998-11-01), Raiden et al.
patent: 5869098 (1999-02-01), Misra et al.
patent: 5980941 (1999-11-01), Raiden et al.
patent: 6916941 (2005-07-01), Christensen et al.
patent: 2001/0049450 (2001-12-01), Ikemoto et al.
patent: 2003/0212128 (2003-11-01), Lundbeck
patent: 2178637 (1995-06-01), None
patent: 2163840 (1996-05-01), None
patent: 2291067 (1998-05-01), None
patent: 2291072 (1998-05-01), None
patent: 2291129 (1999-06-01), None
patent: 2291134 (2000-04-01), None
patent: 0171943 (1986-02-01), None
patent: 0171943 (1988-11-01), None
patent: 0347066 (1989-12-01), None
patent: 0714663 (1996-06-01), None
patent: 0747049 (1996-12-01), None
patent: 0714663 (1997-01-01), None
patent: 1152000 (2001-11-01), None
patent: 1358915 (1974-07-01), None
patent: 2357762 (2001-07-01), None
patent: 9819511 (1998-05-01), None
patent: WO-99/03469 (1999-01-01), None
patent: WO 00/11926 (2000-03-01), None
patent: WO 01/22941 (2001-04-01), None
patent: WO-01/68627 (2001-09-01), None
Webpage from Lundbeck website (www.lundbeck.com), company's activities Sep. 26, 2003.
Webpage from Lundbeck website (www.lundbeck.com): Product information on Cipramil Sep. 26, 2003.
Remington's Pharmaceutical Sciences, 18th Edition, Chapter 89, Oral Solid Dosage Forms, pp. 1633-1658, 1990.
Bhogi B. Sheth, et al., Compressed Tablets, Chapter 3 in Pharmaceutical Dosage Forms: Tablets, vol. 1, H. Lieberman and L. Lachman eds., Marcel Dekker, Inc., New York and Basel, 1979, pp. 109-185.
Chapters 2 to 4 in Pharmaceutical Dosage Forms: Tablets, vol. 1, H. Lieberman and L. Lachman, eds., Marcel Dekker, Inc. New York and Basel 1989, pp. 75-246 (Chaper 2: Tablet and Formulation Design; Chapter 3: Compressed Tablets by Wet Granulation; Chapter 4: Compressed Tablets by Direct Compression).
Keith Marchall, Compression and Consolidation of Powdered Solids, Chapter 4, The Theory and Practise of Industrial Pharmacy, Lieberman, Lachman, and Kanig, eds., 3rd Edition, 1986, pp. 66-99.
Hoener et al., Chapter 4, Factors Influencing Drug Absorption and Drug Availability, Modern Pharmaceutics, 3rd edition, Banker and Rhodes, eds, Marcel Dekker, New York and Basel, 1995, pp. 121-153.
Edward M. Rudnic, et al., Chapter 10, Tablet Dosage Forms, Modern Pharmaceutics, 3d edition, Banker and Rhodes, eds., Marcel dekker, New York and Basel, 1995, pp. 333-394.
Joseph B. Schwartz, et al., Chapter 18, Optimazation Techniques in Pharmaceutical Formulation and Processing, Modern Pharmaceutics, 3rd Edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1995, pp. 727-752.
Gunsel, et al, Chapter 11, Tablets, The Theory and Practice of Industrial Pharmacy, Lieberman, Lachman, and Kanig, eds., 2nd Edition, 1976,pp. 321-358.
Keith Marshall, Chapter 10, Solid Oral Disage Forms, Modern Pharmaceutics, 1st Edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1979, p. 359-427.
Vogel's Texbook of Practical Organic Chemistry, Fourth Edition, pp. 100-263, 1978.
Dr. Fritz Gstirner, Professor fur Pharmazeutische Technologie an der Universitat Bonn, 1973, Einfuhrung in Die Verfahrenstechnik Der Arzneiformung, pp. 201-203 (and English Translation).
O'Connor, R.E. et al., Chapter 91 Powders, Remington: The Science and Practise of Pharmacy, 19th Ed., A. Gennaro, editor, Mack Publishing Co., Easton, 1995, pp. 1598-1613.
Banker, G.S., et al., Chapter 11, Tablets, The Theory and Practice of Industrial Pharmacy, Lieberman, Lachman, and Kanig, eds, 3rd Edition, 1986, pp. 293-345.
Hoener et al., Chapter 4, Factors Influencing Drug Absorption and Drug Availability, Modern Pharmaceutics, 1st edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1979, pp. 143-182.
Joseph B. Schwartz, et al., Chapter 17, Optimization Techniques in Pharmaceutical Formulation and Processing, Modern Pharmaceutics, 1st Edition, Banker and Rhodes, eds., Marcel Dekker, New York and Basel, 1979, pp. 711-734.
N. Hirayama “Crystallization by control of temperature change,“from” Handbook for Preparing Organic Crystals,” Section 3/1/1, pp. 34-35 (Apr. 20, 2000) (and English language translation).
Pierre Carre, “Dissolution dans les Liquides,” Precis de Technologie et de Chimie Industrielle: 319-320, Librairie J.-B. Bailliere et Fils (1938) (and English language translation).
International Serch Report, Jan. 31, 2004.
International Search Report for PCT/DK02/00513.
Kirk-Othmer,Encyclopedia of Chemical Technology, Second Edition, vol. 6:482, New York, John Wiley & Sons.
Kunsemuller, Johannes Ed.,Meyers Lexikon der Technik und der exakten Naturwissenschaften: 1151, Mannheim/Wien/Zurich: Bibliographisches Institute (1970).
Bates, Robert B., et al., Ed.Research Techniques in Organic Chemistry: 50-52, Englewood Cliffs, NJ: Prentice Hall, Inc. (1971).
Organikum: Organisch-Chemisches Grundpraktikum: pp. 39-41, Veb Deutscher Vertag Der Wissenschaften, Berlin (1974).
Hyttel John, Citalopram—Pharmacological Profile of a Specific Serotonin Uptake Inhibitor with Antidepressant Avtivity,Prog. Neuro-Psychopharmacol&Biol. Psychiat. 6:277-295 (1982).
Gravem, A., et al. “A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients,” Acta Psychiatr. Scand. 75: 478-486 (1987).
Fumiss, Brian, Ed.,Vogel's Textbook of Practical Oganic Chemistry, Fifth Edition: 135-6, New York: Longman Scientific & Technical (John Wiley & Sons, Inc. (1989).
Numberg, E., et al., Ed.,Hagers Handbuch der pharmazeutishen Praxis, vol. 5: 549-51, Springer-Verlag: Wissenschafflicher Beirat (1991).
Kirk-Othmer,Encyclopedia of Chemical Technology, Fourth Edition, vol. 7:683-5, New York: John Wiley & Sons (1993).
“Repetition of Example 2, col. 6, lines 7 to 36 of U.S. patent 4,943,590.”
Ausdruck “Inhouse Pharmacy Lexapro”—Celexa and other antidepressant medications.
“Herstellung von 1-(3-Dimethylaminopropyl)-1-(4′-fluorophenyl)-1,3-dihydroisobenzo-furan-5-carbonitril-hydrobromid mach EP 0171943 A1, Beispiel 2 in Verbindung mit Beispeil 1.”
“Precis de Technologie Et De Chimie Industrielle Tome Premier Les Problemes Generaux De L'Industrie Chimique Par Pierre Carre, Paris, 1938, Seiten 319 bis 320.”
Notice of Opposition to European Patent No. 1 414 435 filed by Egis Gyogyszergyar Rt. (Oct. 11, 2005).
Andresen Lene
Assenza Sebastian P.
Christensen Troels Volsgaard
Elema Michiel Onne
Liljegren Ken
Chandrakumar Nizal S
Darby & Darby P.C.
H. Lundbeck A/S
Seaman D. Margaret
LandOfFree
Crystalline composition containing escitalopram does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline composition containing escitalopram, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline composition containing escitalopram will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3966511